AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Two Day Course: Drug Development Process from Concept to Market - July 13-14, 2021 - ResearchAndMarkets.com

May 26, 2021 GMT

DUBLIN--(BUSINESS WIRE)--May 26, 2021--

The “The Drug Development Process from Concept to Market” conference has been added to ResearchAndMarkets.com’s offering.

This course is designed to cater for employees of pharmaceutical companies who would like an understanding of the drug development and regulatory approval process. The course starts by considering the global pharmaceutical market, important therapeutic areas and the roles of different pharmaceutical professionals in the development process, as well as a definition of drugs and medical devices.

ADVERTISEMENT

The drug development process, from discovery to post-marketing surveillance, is then explained. Topics include the identification of drug targets, synthesis of chemical drugs and the development of biologics, pharmacokinetics and toxicity screening, pre-clinical development, clinical studies, regulatory submissions, managing post-approval change, pharmacovigilance and an overview of regulations governing drug manufacture and distribution.

Learning Objectives:

  • The size of the global pharmaceutical market and the key therapeutic areas being addressed by innovator companies
  • The roles of different pharmaceutical professionals
  • Typical costs and timelines associated with drug development
  • How new drugs are developed against targets in the human body
  • Reasons why drugs fail during development
  • Factors affecting oral bioavailability
  • How drugs are screened for toxicity
  • The potential influence of polymorphism, salt form and isomerism on efficacy and safety
  • How formulation can affect drug performance
  • How the safety and efficacy of drug products are ensured during QC release testing
  • The information obtained at each stage of clinical research
  • The structure of regulatory submissions
  • How post-approval changes to drug products are managed
  • How the manufacture and distribution of marketed drug products are controlled

Who Should Attend:

  • Non-scientific employees of pharmaceutical companies who would like to understand how drugs are developed (e.g. IT, human resources, engineering and administrative staff)
  • Recently-appointed scientific staff with no previous experience of the pharmaceutical industry
  • Any pharmaceutical employee wishing to improve their knowledge of drug development

Agenda:

Time: 12:30pm - 5:00pm EDT

The global pharmaceutical market

ADVERTISEMENT

  • Size and key therapeutic areas
  • Regional differences
  • Market shares of chemical and biological drugs
  • Roles of drug development professionals

Overview - development of drug products

  • Product types and routes of administration
  • The drug development process
  • Risks in drug development

Drug discovery

  • Drug targets
  • The Human Genome Project
  • Lead compound identification and optimization

Break

Pharmacokinetics and toxicity

  • Drug plasma concentration profiles
  • Absorption, distribution, metabolism and elimination of drugs
  • First-pass metabolism
  • Types of toxicity screening

Break

Pre-clinical development

  • Polymorph and salt form screening
  • Solubility, permeability and oral bioavailability
  • Optical isomerism
  • Formulation options for improving bioavailability
  • Common formulation types
  • Critical quality attributes
  • In-process controls and release testing

Clinical research

  • Phases of clinical development
  • Establishing safety and efficacy/bioequivalence
  • Clinical study design
  • Adverse event reporting
  • Impact of mobile computing on clinical research

Regulatory submissions

  • The application process for chemical and biologic drug products - US and EU
  • The Common Technical Document
  • CTD modules
  • Regional administrative information

Break 15 mins

Post-approval change

  • Current situation
  • Problems concerning product improvement
  • New ICH Q12 - the promise of easier post-approval change

Pharmacovigilance Important elements of regulation (US and EU)

  • Drug product manufacture
  • Distribution
  • ICH guidance

Final questions, feedback and close

For more information about this conference visit https://www.researchandmarkets.com/r/jbgmtj

View source version on businesswire.com:https://www.businesswire.com/news/home/20210526005554/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 05/26/2021 06:52 AM/DISC: 05/26/2021 06:52 AM

http://www.businesswire.com/news/home/20210526005554/en